402 related articles for article (PubMed ID: 25107879)
1. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
Ho TW; Connor KM; Zhang Y; Pearlman E; Koppenhaver J; Fan X; Lines C; Edvinsson L; Goadsby PJ; Michelson D
Neurology; 2014 Sep; 83(11):958-66. PubMed ID: 25107879
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.
Ho TW; Ho AP; Ge YJ; Assaid C; Gottwald R; MacGregor EA; Mannix LK; van Oosterhout WP; Koppenhaver J; Lines C; Ferrari MD; Michelson D
Cephalalgia; 2016 Feb; 36(2):148-61. PubMed ID: 25926620
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
[TBL] [Abstract][Full Text] [Related]
4. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
Ho TW; Ho AP; Chaitman BR; Johnson C; Mathew NT; Kost J; Fan X; Aurora SK; Brandes JL; Fei K; Beebe L; Lines C; Krucoff MW
Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
[TBL] [Abstract][Full Text] [Related]
5. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.
Depré M; Macleod C; Palcza J; Behm M; de Lepeleire I; Han T; Panebianco D; Smith W; Blanchard R; Chodakewitz J; Murphy M; de Hoon J
Cephalalgia; 2013 Dec; 33(16):1292-301. PubMed ID: 23798725
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine.
Hewitt DJ; Martin V; Lipton RB; Brandes J; Ceesay P; Gottwald R; Schaefer E; Lines C; Ho TW
Headache; 2011 Apr; 51(4):533-43. PubMed ID: 21457238
[TBL] [Abstract][Full Text] [Related]
7. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
[TBL] [Abstract][Full Text] [Related]
8. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
Tfelt-Hansen P
Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
[TBL] [Abstract][Full Text] [Related]
9. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
Tepper SJ; Cleves C
Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
[TBL] [Abstract][Full Text] [Related]
10. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
Dodick DW; Kost J; Assaid C; Lines C; Ho TW
Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
[TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled trial of telcagepant over four migraine attacks.
Ho AP; Dahlöf CG; Silberstein SD; Saper JR; Ashina M; Kost JT; Froman S; Leibensperger H; Lines CR; Ho TW
Cephalalgia; 2010 Dec; 30(12):1443-57. PubMed ID: 20974601
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.
Chaitman BR; Ho AP; Behm MO; Rowe JF; Palcza JS; Laethem T; Heirman I; Panebianco DL; Kobalava Z; Martsevich SY; Free AL; Bittar N; Chrysant SG; Ho TW; Chodakewitz JA; Murphy MG; Blanchard RL
Clin Pharmacol Ther; 2012 Mar; 91(3):459-66. PubMed ID: 22278333
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
Cui XP; Ye JX; Lin H; Mu JS; Lin M
Pain Pract; 2015 Feb; 15(2):124-31. PubMed ID: 24382126
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
[TBL] [Abstract][Full Text] [Related]
15. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate.
Edvinsson L; Linde M
Lancet; 2010 Aug; 376(9741):645-55. PubMed ID: 20416945
[TBL] [Abstract][Full Text] [Related]
16. Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study.
Behm MO; Blanchard RL; Murphy MG; Palcza JS; Harris DE; Butterfield KL; Smith WB; Preston RA; Chodakewitz JA; Krucoff MW
Headache; 2011 Jun; 51(6):954-60. PubMed ID: 21631478
[TBL] [Abstract][Full Text] [Related]
17. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
18. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
Ho TW; Olesen J; Dodick DW; Kost J; Lines C; Ferrari MD
Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
20. Molecule of the month. Telcagepant.
Drug News Perspect; 2009 Mar; 22(2):115. PubMed ID: 19330169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
